BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 16603535)

  • 1. Characterization of the murine leukemia virus protease and its comparison with the human immunodeficiency virus type 1 protease.
    Fehér A; Boross P; Sperka T; Miklóssy G; Kádas J; Bagossi P; Oroszlan S; Weber IT; Tözsér J
    J Gen Virol; 2006 May; 87(Pt 5):1321-1330. PubMed ID: 16603535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro.
    Maguire MF; Guinea R; Griffin P; Macmanus S; Elston RC; Wolfram J; Richards N; Hanlon MH; Porter DJ; Wrin T; Parkin N; Tisdale M; Furfine E; Petropoulos C; Snowden BW; Kleim JP
    J Virol; 2002 Aug; 76(15):7398-406. PubMed ID: 12097552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteolytic activity of human immunodeficiency virus Vpr- and Vpx-protease fusion proteins.
    Wu X; Liu H; Xiao H; Kappes JC
    Virology; 1996 May; 219(1):307-13. PubMed ID: 8623547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered gag polyprotein cleavage specificity of feline immunodeficiency virus/human immunodeficiency virus mutant proteases as demonstrated in a cell-based expression system.
    Lin YC; Brik A; de Parseval A; Tam K; Torbett BE; Wong CH; Elder JH
    J Virol; 2006 Aug; 80(16):7832-43. PubMed ID: 16873240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of sequence polymorphism and drug resistance on two HIV-1 Gag processing sites.
    Fehér A; Weber IT; Bagossi P; Boross P; Mahalingam B; Louis JM; Copeland TD; Torshin IY; Harrison RW; Tözsér J
    Eur J Biochem; 2002 Aug; 269(16):4114-20. PubMed ID: 12180988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blocking of human immunodeficiency virus type-1 virion autolysis by autologous p2(gag) peptide.
    Misumi S; Morikawa Y; Tomonaga M; Ohkuma K; Takamune N; Shoji S
    J Biochem; 2004 Mar; 135(3):447-53. PubMed ID: 15113844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bovine leukemia virus protease: comparison with human T-lymphotropic virus and human immunodeficiency virus proteases.
    Sperka T; Miklóssy G; Tie Y; Bagossi P; Zahuczky G; Boross P; Matúz K; Harrison RW; Weber IT; Tözsér J
    J Gen Virol; 2007 Jul; 88(Pt 7):2052-2063. PubMed ID: 17554040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Purification and biochemical characterization of recombinant simian immunodeficiency virus protease and comparison to human immunodeficiency virus type 1 protease.
    Grant SK; Deckman IC; Minnich MD; Culp J; Franklin S; Dreyer GB; Tomaszek TA; Debouck C; Meek TD
    Biochemistry; 1991 Aug; 30(34):8424-34. PubMed ID: 1883829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amino acid substitutions in Gag protein at non-cleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors.
    Gatanaga H; Suzuki Y; Tsang H; Yoshimura K; Kavlick MF; Nagashima K; Gorelick RJ; Mardy S; Tang C; Summers MF; Mitsuya H
    J Biol Chem; 2002 Feb; 277(8):5952-61. PubMed ID: 11741936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteolytic activity of novel human immunodeficiency virus type 1 proteinase proteins from a precursor with a blocking mutation at the N terminus of the PR domain.
    Zybarth G; Kräusslich HG; Partin K; Carter C
    J Virol; 1994 Jan; 68(1):240-50. PubMed ID: 8254734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of inhibition of the retroviral protease by a Rous sarcoma virus peptide substrate representing the cleavage site between the gag p2 and p10 proteins.
    Cameron CE; Grinde B; Jentoft J; Leis J; Weber IT; Copeland TD; Wlodawer A
    J Biol Chem; 1992 Nov; 267(33):23735-41. PubMed ID: 1331099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of human endogenous retrovirus-K10 protease in cell-free and cell-based assays.
    Kuhelj R; Rizzo CJ; Chang CH; Jadhav PK; Towler EM; Korant BD
    J Biol Chem; 2001 May; 276(20):16674-82. PubMed ID: 11278433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective killing of human immunodeficiency virus infected cells by non-nucleoside reverse transcriptase inhibitor-induced activation of HIV protease.
    Jochmans D; Anders M; Keuleers I; Smeulders L; Kräusslich HG; Kraus G; Müller B
    Retrovirology; 2010 Oct; 7():89. PubMed ID: 20950436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional characterization of the protease of human endogenous retrovirus, K10: can it complement HIV-1 protease?
    Towler EM; Gulnik SV; Bhat TN; Xie D; Gustschina E; Sumpter TR; Robertson N; Jones C; Sauter M; Mueller-Lantzsch N; Debouck C; Erickson JW
    Biochemistry; 1998 Dec; 37(49):17137-44. PubMed ID: 9860826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A human immunodeficiency virus type 1 protease biosensor assay using bioluminescence resonance energy transfer.
    Hu K; Clément JF; Abrahamyan L; Strebel K; Bouvier M; Kleiman L; Mouland AJ
    J Virol Methods; 2005 Sep; 128(1-2):93-103. PubMed ID: 15951029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural and biochemical characterization of the inhibitor complexes of xenotropic murine leukemia virus-related virus protease.
    Li M; Gustchina A; Matúz K; Tözsér J; Namwong S; Goldfarb NE; Dunn BM; Wlodawer A
    FEBS J; 2011 Nov; 278(22):4413-24. PubMed ID: 21951660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo processing of Pr160gag-pol from human immunodeficiency virus type 1 (HIV) in acutely infected, cultured human T-lymphocytes.
    Lindhofer H; von der Helm K; Nitschko H
    Virology; 1995 Dec; 214(2):624-7. PubMed ID: 8553565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1.
    Barrie KA; Perez EE; Lamers SL; Farmerie WG; Dunn BM; Sleasman JW; Goodenow MM
    Virology; 1996 May; 219(2):407-16. PubMed ID: 8638406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the HIV-1 and HIV-2 proteinases using oligopeptide substrates representing cleavage sites in Gag and Gag-Pol polyproteins.
    Tözsér J; Bláha I; Copeland TD; Wondrak EM; Oroszlan S
    FEBS Lett; 1991 Apr; 281(1-2):77-80. PubMed ID: 2015912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of a murine leukemia virus Gag-Escherichia coli RNase HI fusion polyprotein significantly inhibits virus spread.
    VanBrocklin M; Ferris AL; Hughes SH; Federspiel MJ
    J Virol; 1997 Apr; 71(4):3312-8. PubMed ID: 9060701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.